On March 6, 2017, Bristol-Myers Squibb Holdings Pharma, Ltd. submitted a notification of proposed production activity to the FTZ Board within Subzone 7J, in Manati, Puerto Rico.
The notification was processed in accordance with the regulations of the FTZ Board (15 CFR part 400), including notice in the Federal Register inviting public comment (82 FR 13578, March 14, 2017). On July 5, 2017, the applicant was notified of the FTZ Board's decision that no further review of the activity is warranted at this time. The production activity described in the notification was authorized, subject to the FTZ Act and the FTZ Board's regulations, including Section 400.14.
Dated: July 7, 2017.
Acting Executive Secretary.
[FR Doc. 2017-14612 Filed 7-11-17; 8:45 am]
BILLING CODE 3510-DS-P